Two years ago you could sit a cardiology board and never be asked about the tricuspid valve beyond Ebstein, carcinoid and the Carvallo sign. That has changed. Tricuspid valve intervention now has randomised outcome data, a validated risk score and a class recommendation in the 2025 ESC/EACTS guideline — the combination that turns a quiet topic into an examined one.
What follows is organised the way an examiner thinks about tricuspid valve intervention: seven high-yield blocks, each ending in the fact that gets asked. Carry one idea above all others. The randomised evidence supports symptom and TR-grade benefit, not a demonstrated mortality benefit. Overstate the mortality case and you lose marks; say where benefit is proven and when the answer is no procedure, and you gain them.
Board fact 1: classify the mechanism before you discuss tricuspid valve intervention
Every strong answer opens with mechanism. Primary TR — carcinoid, rheumatic, endocarditis, prolapse, trauma — is the minority. The bulk is secondary, and the examiner wants it subdivided.
Atrial versus ventricular secondary TR
Atrial secondary TR follows annular dilatation in long-standing atrial fibrillation with a preserved, non-dilated RV: normal leaflets, lost coaptation. Ventricular secondary TR follows RV dilatation, papillary displacement and tethering. CIED lead-related TR is a third stem — impingement, adhesion, perforation or lead–leaflet interference. Mechanism predicts what a device can do: mobile leaflets with a dilated annulus suit edge-to-edge repair, severe tethering with a wide gap pushes towards replacement.
The five-grade scale and RV–PA coupling
Grade TR as mild, moderate, severe, massive or torrential; the extension exists because outcomes keep worsening above the old ceiling, where trial populations sit. Pair grade with RV–PA coupling as TAPSE/PASP: severe TR with uncoupled physiology and precapillary pulmonary hypertension is a different animal from severe TR with a coupled RV.
Board fact 2: the forgotten valve, and why tricuspid valve intervention arrived late
TR earned its label for three reasons: isolated tricuspid surgery carried an operative mortality no other valve operation tolerated, so referral collapsed; oedema, ascites and hepatic congestion are non-specific; and diuretics mask the picture until the RV is beyond rescue.
What changed was procedural. Percutaneous access, better intraprocedural imaging and purpose-built devices made tricuspid valve intervention feasible in patients who would never survive sternotomy. TRILUMINATE Pivotal, Tri.Fr and TRISCEND II then made the field randomised. bRIGHT (JACC 2024;84:607–616) frames the real world: 511 patients, 26 sites, 88% massive or torrential TR, 81% moderate or less at one year, KCCQ +19 — the population treated outside trials is sicker, not healthier.
Board fact 3: TRILUMINATE and the KCCQ-only caveat
TRILUMINATE Pivotal randomised 572 patients (mean age 78.1, 58.9% female) to T-TEER with TriClip or medical therapy. The one-year primary hierarchical composite was positive, carried by KCCQ improvement alone, +12.3 points. Death and heart failure hospitalisation contributed nothing. That is the highest-yield sentence here.
Two-year data (Circulation 2025, ACC.25) moved matters forward without overturning them: heart failure hospitalisation 0.19 versus 0.26 per patient-year, joint frailty model HR 0.72, p=0.02. Moderate-or-less TR at two years was 84% with device versus 21% among controls remaining on medical therapy. Stroke 1.9% versus 2.5%, new permanent pacemaker 5.5%.
Now the number that catches people out: 142 of 241 eligible controls crossed over after year one. Quote 21%, and say explicitly that it excludes crossovers. Tri.Fr (JAMA 2024) confirms the direction: 300 patients, 24 French and Belgian centres, Packer composite improved in 74.1% versus 40.6%, p<0.0001, KCCQ 69.9 versus 55.4, deployment success 97.3%, 30-day major adverse events 0.7%.
Board fact 4: T-TEER versus TTVR, the trade-off at the centre of tricuspid valve intervention
TRISCEND II randomised 400 patients 2:1 to EVOQUE transcatheter tricuspid valve replacement or medical therapy. Win ratio 2.02 (1.56–2.62). Mild-or-less TR at 30 days was 95.3% versus 2.3%, an abolition repair cannot match. The price sits on safety: new pacemaker or CIED 24.7%, severe bleeding 10.4%, cardiovascular death 3.1% at 30 days.
Set 24.7% against T-TEER’s 5.5% and the examiner’s real question appears: not “which device is better” but “what are you trading” — conduction and bleeding risk for complete TR elimination. At ACC.26, two-year TRISCEND II data showed TR control sustained around 95% and symptom benefit sustained, with no all-cause mortality difference in the primary comparison.
Why device selection is an imaging answer
Device choice in tricuspid valve intervention is settled at the imaging table: coaptation gap, tethering, vena contracta, lead position, RV size and function. Candidates who describe a structured Heart Team pathway — imaging, risk score, right heart catheterisation, then device — outscore those reaching for hardware first. The cardiology learning centre revision library works it case by case.
Board fact 5: TRI-SCORE and the discipline of futility
TRI-SCORE (Eur Heart J 2022;43:654–662) was derived in 466 patients across 12 French centres to predict in-hospital and post-operative mortality after isolated tricuspid surgery. Eight variables, maximum 12 points, bias-corrected AUROC 0.753 against 0.629 for EuroSCORE II.
| TRI-SCORE variable | Threshold that scores |
|---|---|
| Age | ≥70 years |
| Functional class | NYHA III–IV |
| Right-sided heart failure | Clinical signs present |
| Daily furosemide dose | ≥125 mg |
| Renal function | GFR <30 mL/min |
| Bilirubin | Elevated total bilirubin |
| LV function | LVEF <60% |
| RV function | Moderate or severe dysfunction |
| Score band | In-hospital / post-operative mortality |
| 0–3 | 1% |
| 4–5 | 14–18% |
| 6–7 | 25–32% |
| ≥8 | 33–60% |
The band that decides management is ≥8. A 33–60% mortality range is not a figure you consent a patient through; it says the disease has travelled beyond the valve into liver, kidney and RV. The guideline endorses TRI-SCORE for futility, and saying that tricuspid valve intervention can be contraindicated by physiology rather than anatomy earns marks.
Board fact 6: what the guidelines say about tricuspid valve intervention
Reliably examined, because the two documents sit one randomised era apart.
| Domain | 2025 ESC/EACTS | 2020 ACC/AHA |
|---|---|---|
| Heart Team evaluation | Class I, Level C | Not framed this way |
| Transcatheter tricuspid intervention | Class IIa, Level A, symptomatic high-risk patients on optimal medical therapy | Predates the randomised era |
| Explicit conditions | No severe RV dysfunction; no precapillary PH | Not addressed |
| Tricuspid surgery with left-sided valve surgery | Within the surgical pathway | Class I — its only Class I surgical recommendation |
| Severe primary TR with right heart failure | Heart Team pathway | Class IIa for surgery |
| Futility assessment | TRI-SCORE endorsed | Not addressed |
Two things to say aloud. First, the Class IIa, Level A recommendation for tricuspid valve intervention is conditional: drop the RV dysfunction and precapillary pulmonary hypertension caveats and you have misquoted it. Second, the 2020 ACC/AHA document is not wrong, it predates the randomised evidence, and its only Class I surgical recommendation is tricuspid surgery at the time of left-sided valve surgery.
Board fact 7: the traps examiners set
Marks here are lost, not won. The recurring traps around tricuspid valve intervention:
- The crossover-inflated control figure. Coverage quoting 63% of TRILUMINATE controls at moderate-or-less TR is counting crossovers. The medical-therapy figure is 21%.
- The 98-patient single-arm three-year data quoted as randomised. That cohort (JACC Cardiovasc Interv 2024) reported 79% moderate or less, NYHA III/IV 76% to 19%, mortality 27%, HFH 0.56 to 0.14 per patient-year. Say single-arm, every time.
- Claiming a mortality benefit. None has been shown in a randomised comparison.
- Quoting as-treated secondary analyses. Where crossover is permitted these are confounded by design. Stay with the primary.
- Ignoring the guideline conditions, or using EuroSCORE II. The RV and pulmonary hypertension caveats are part of the recommendation, and TRI-SCORE discriminates better (0.753 versus 0.629).
Worked cases sit in these structural heart teaching notes; the interventional cardiology course catalogue covers imaging assessment.
Five single-best-answer questions
Q1. In TRILUMINATE Pivotal, the positive one-year primary composite was driven by:
- All-cause mortality
- Heart failure hospitalisation
- KCCQ improvement alone
- Cardiovascular mortality and stroke
- Reduced diuretic dose
Answer: C. The composite was positive on a +12.3-point KCCQ gain; death and heart failure hospitalisation contributed nothing at one year. This is why claiming a randomised mortality benefit for tricuspid valve intervention is an error. The hospitalisation signal (0.19 versus 0.26 per patient-year) came at two years.
Q2. A 79-year-old with torrential secondary TR has a TRI-SCORE of 9. The mortality band is:
- 1%
- 14–18%
- 25–32%
- 33–60%
- Not estimable
Answer: D. A score of ≥8 predicts 33–60% mortality, the band that should trigger a futility discussion rather than a consent conversation. TRI-SCORE uses eight variables to a maximum of 12 points and outperforms EuroSCORE II (0.753 versus 0.629).
Q3. Which finding best distinguishes EVOQUE TTVR from T-TEER?
- Higher stroke rate with TTVR
- New pacemaker or CIED 24.7% with TTVR versus 5.5% with T-TEER
- More device embolisation with T-TEER
- Greater residual TR with TTVR
- No meaningful difference
Answer: B. Conduction injury is the defining cost of replacement, alongside severe bleeding in 10.4% and cardiovascular death of 3.1% at 30 days. Against that, TTVR achieved mild-or-less TR in 95.3% versus 2.3%. You trade conduction and bleeding risk for completeness.
Q4. In the 2025 ESC/EACTS guideline, what class and level applies to transcatheter tricuspid valve intervention in symptomatic high-risk patients on optimal medical therapy?
- Class I, Level A
- Class I, Level C
- Class IIa, Level A
- Class IIb, Level B
- Class III, Level C
Answer: C. Class IIa, Level A, conditional on the absence of severe RV dysfunction and precapillary pulmonary hypertension. Class I, Level C is the separate Heart Team recommendation, and the distractor most candidates take. The same guideline endorses TRI-SCORE for futility.
Q5. A presenter states that 63% of TRILUMINATE controls reached moderate-or-less TR at two years. The correct critique is:
- Correct, but only for primary TR
- It includes crossovers; the medical-therapy rate was 21%
- It comes from the single-arm 98-patient cohort
- It refers to mild-or-less TR
- It describes the device arm
Answer: B. 142 of 241 eligible controls crossed over after year one, so any figure including them no longer describes medical therapy. Among controls who stayed on medical therapy the rate was 21%, against 84% with device. Spotting crossover contamination is the skill tested here.
Boards keep returning here because the evidence is unsettled, and unsettled evidence rewards precise quotation. Learn the seven blocks, keep the trap list beside them, and open every answer on tricuspid valve intervention the same way: mechanism, RV–PA coupling, TRI-SCORE, device. The candidate who explains why tricuspid valve intervention improves symptoms and TR grade without a demonstrated mortality benefit, and knows when the right answer is no procedure, passes.
Written and clinically reviewed by Dr A M Thirugnanam, MD, MSICP, FSCAI, Ph.D., Senior Interventional Cardiologist. Last reviewed 6 August 2026. This article is for medical education and does not replace individual clinical judgement or local protocols.
